Intraocular pressure (IOP) rise after anti-vascular endothelial growth factor (VEGF) treatment for neovascular age-related macular degeneration (AMD) can be either short-term or longterm and may require medical intervention. Short-term IOP spikes are a fairly common and well recognized complication of anti-VEGF injections. Long-term IOP rise is less well-understood and disputed as a complication by some authors. We try to review current literature on the subject and especially studies focused on the prevalence of this complication, speculate on possible mechanisms of IOP rise and discuss correlations of long-term IOP rise with the nature of the injected agent, average number of injections, previous glaucoma history and other factors.
INTRODUCTION
Intravitreal antivascular endothelial growth factors (antiVEGFs) are currently the mainstay of treatment for choroidal neovascularization due to age-related macular degeneration (AMD). Based on well-conducted studies, 1-3 ranibizumab (Lucentis, Genentech, San Francisco, CA, USA) and bevacizumab (Avastin, Genentech) are used all over the world on many thousands of patients with this debilitating disease. Ranibizumab is a F ab fragment of a recombinant humanized immunoglobulin, targeting VEGF-A and has Food and Drug Administration (FDA) approval for treating wet AMD. Bevacizumab is a full size humanized monoclonal antibody targeting VEGF-A and is approved by the FDA for the treatment of various cancers, though not specifically for intravitreal use. The widespread use of both these agents in the eye is not without side effects, however, ranging from innocuous subconjunctival hemorrhage to devastating endophthalmitis. One of these side effects has come into focus lately and is related with the rise of intraocular pressure (IOP), which can be transient or permanent. We will try to address this topic providing insight to the prevalence of IOP rise related to anti-VEGF use based on reports on such cases so far, possible mechanisms implicated and proposed prevention strategies.
SHORT-TERM IOP INCREASE
A transient increase in IOP is a well-known complication of intravitreal injections (whether they are anti-VEGF or not) and has been reported in the initial MARINA and ANCHOR studies 1, 2 for ranibizumab treatment, although in only a few patients. This is probably related to the immediate increase of intraocular volume together with factors, such as scleral rigidity and is corroborated by the fact that hyperopic (shorter and more rigid) eyes show a greater rise in IOP immediately postinjection than longer eyes. 4 Other studies have confirmed these findings [5] [6] [7] [8] 
PREVALENCE OF LONG-TERM IOP INCREASE
The prevalence of long-term IOP rise after anti-VEGF injections is reported as variable in the literature. The original MARINA and ANCHOR trials 1,2 did not find any significant long-term effects on IOP after 2 years of anti-VEGF treatment. On the other hand, a post hoc analysis showed that 2.1% of eyes in the MARINA and 3.6% of the eyes in the ANCHOR trials met the criteria for long-term IOP rise at the 2 years follow-up, compared with 0.4% and 0% of eyes in the control groups respectively. 14 Bakri et al 15 first reported sustained IOP rise after ranibizumab injections requiring medical treatment in a small series of four patients and Kahook et al reported similar findings in six patients. 16 Several studies followed reporting prevalence of long-term IOP rise after treatment with ranibizumab and/ or bevacizumab injections.
17-22
Adelman et al 17 reported a prevalence of four of 116 in patients receiving anti-VEGF injections (3.45%). In their study, among the 116 patients with wet AMD, who received intravitreal injections, 57 received ranibizumab only, 40 received bevacizumab only and 19 received both agents. None of the four patients had a history of glaucoma or ocular hypertension (OHT). The mean number of anti-VEGF injections prior to raised IOP was 13.3 (range, 3-19). Good et al 18 reviewed 215 eyes receiving anti-VEGF treatment and reported 13 eyes (6%) in total requiring IOP lowering intervention. In eyes receiving ranibizumab only the prevalence was 3.1% (3/96 eyes) and in eyes receiving bevacizumab only the prevalence was 9.9% (10/101 eyes), the difference between the two drugs barely significant (p = 0.049). In this study, it was found that patients with pre-existing glaucoma experienced higher rates of elevated IOP compared with patients without pre-existing glaucoma (33 vs 3.1% respectively, p < 0.001). Of note also, that the glaucoma subgroup had a lower median number of injections compared with the nonglaucoma group (6 and 9.5 respectively, p = 0.031). Hoang et al 19, 20 presented data from a cohort of patients, the second paper with additional data on more patients. In their first study, the rate of longterm raised IOP after anti-VEGF injections was reported in uniocularly-injected patients (the other eye served as control). According to the results, 11.6% of treated vs 5.3% of untreated/control eyes experienced long-term IOP elevation (p = 0.02). Of the factors considered, only the total number of injections showed a statistically significant association with IOP elevation (p = 0.05). In the second paper, they presented data on 449 eyes (328 patients) receiving anti-VEGF injections, this time including patients injected bilaterally. Again they reported association with the total number of injections, with increased odds ratio (OR = 16.1, p = 0.008) of sustained IOP elevation in eyes receiving > 29 injections compared with eyes receiving < 12 injections. The authors report that the study was not adequately powered to distinguish differences between patients receiving ranibizumab vs bevacizumab. Wehrli et al 21 on the contrary reported a low prevalence of long-term IOP raise after anti-VEGF injections. In their study, they included data from 302 injected eyes and 226 control (noninjected), fellow eyes. Of the 302 eyes with wet AMD, 270 were nonglaucomatous and 32 had glaucoma. These groups received on average 8.4 and 7.9 anti-VEGF injections respectively, whereas 34% of the eyes were treated exclusively with ranibizumab, 32% received bevacizumab only and 34% received both agents. Overall, 5 of 302 injected eyes developed long-term IOP increase compared with 7 of 226 control eyes, with a median time to development of peak IOP after the last injection of 14 weeks. The median number of injections before peak IOP was 8.
None of the 26 patients in this study, who received more than 20 injections developed the aforementioned complication. They concluded that the incidence of developing sustained IOP increase per eye-year was 0.51% for injected eyes compared to 1.00% in control eyes, a difference that was not statistically significant [hazard ratio = 0.48; 95% confidence interval (CI): 0.11-2.23]. In eyes with concomitant glaucoma, the incidence was 3.1% per All the above studies share a common point and that is their retrospective nature with all inherent restrictions present in retrospective studies. They provide though a useful insight in cases with long-term IOP increase after anti-VEGF injections and their management. Together with studies 23, 24 which focus specifically on treatment of these cases, they provide evidence that most eyes are well controlled after medical or laser treatment (SLT) with a few exceptions 24 requiring trabeculectomy. An overview of the studies reporting prevalence and possible causative factors of long-term IOP increase after anti-VEGF treatment is presented in Table 1 .
POSSIBLE MECHANISMS FOR LONG-TERM IOP INCREASE
The mechanism of long-term IOP rise associated with anti-VEGF treatment is more difficult to ascertain than the one of short-term IOP spikes and is possibly multifactorial.
There have been conflicting results in studies investigating direct toxicity of these agents 25, 26 in cells and structures of the eye. A case report 27 suggested possible inflammation in the trabecular area as a direct cause of increased IOP, but this was not observed in eyes from larger series. There has also been some speculation regarding differences in the prevalence (and the mechanism implicated) between the two anti-VEGF agents used nowadays, i.e. between ranibizumab and bevacizumab. Bevacizumab has a molecular weight of 149 kDa and is three times larger than ranibizumab (48 kDa). It has been suggested 15 that these molecules (bevacizumab in particular, both because of size and longer half-life in the vitreous) can accumulate in the trabeculum and/or Schlemm's canal, especially after long-term repeated administration and cause either direct obstruction or indirect change of outflow facility. Another mechanism that has been proposed involves possible protein aggregates and/or silicone droplets contamination and outflow obstruction from the syringes used. It is possible that this contamination increases by freezing/thawing of anti-VEGF agents or any other mishandling during storage. [28] [29] [30] In addition, ranibizumab comes in a single dose vial ready for use which is drown into the syringe immediately before injection, while bevacizumab is drown from a larger vial, usually in multiple syringes, which are frozen for variable time periods, therefore increasing the risk not only of aggregates but of sterile and infectious endophthalmitis as well. In a recent study, 31 it was noted that patients receiving bevacizumab were 12 times more likely to develop severe intraocular inflammation following each injection than those who received ranibizumab. In many countries, this procedure is carried in compounding pharmacies and, therefore, ophthalmologists do not interfere with drug storage and preparation but just deliver the injection. In the Good et al study, 18 there was a disparity in long-term IOP increase in eyes injected with bevacizumab between the two centers participating in the study. The authors attributed these findings to the fact that two different compounding pharmacies were bevacizumab providers for the two centers, with differences in preparation, freezing time and storage procedures. A similar explanation is noted in the Mathalone et al paper, 22 although in their study storage time did not exceed 3 days. In the Wehrli et al paper, 21 despite storage time for bevacizumab being up to 2 weeks, no significant long-term IOP increase was noted. Total number of received injections has also been implicated as a causative factor. Good et al did not find any association. Tseng et al 23 report a series of eyes that developed glaucoma after a mean of 20 injections (range: 8-40), whereas in the other studies, the number of eyes with more than 20 injections is low. Hoang et al 20 on the contrary, reported the total number of injections as being a risk factor, especially if the number of injections exceeded 29 (16.1 times the risk than eyes receiving fewer than 12 injections). Of importance here, is the large number of eyes that received more than 22 injections (224 eyes), whereas in other studies, the number of eyes with more than 22 injections is much lower.
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The interval between injections has also been reported to be important for long-term IOP raise. Mathalone et al found that, if the interval was less than 8 weeks, the risk was higher. Good et al did not observe any correlation. Two of the eyes in the Tseng paper returned to normal IOPs after switching from 'regular interval' dosing to a kind of 'treat and extend' dosing without any other treatment, suggesting that increasing the interval between injections may allow the agent to be cleared from the eye and thus IOP normalization.
Previous glaucoma or OHT has been implicated as a causative factor for postinjection long-term IOP raise. Good et al noted this finding and suggested that eyes with an already compromised aqueous humor outflow system may be more prone to developing elevated IOP in this setting. Wehrli et al report no association and Adelman et al report no previous glaucoma or OHT in any affected eye in their series. Mathalone et al did not report any association but raise the posibility of having a small number of glaucomatous eyes in their study. Hoang et al also did not report any association but note that inclusion criteria in their study excluded three patients with pre-existing glaucoma with poorly controlled IOP at baseline.
CONCLUSION
It is difficult to have definite conclusions because of the many variables implicated, lack of controls in most and retrospective nature of all available studies, sometimes excluding any relation between injections and long-term increased IOP. Different anti-VEGF agents, combination of the two agents, variable schemes of treatment with differences in intervals between injections and their total number, differences in preparation, handling, freezing and storage for bevacizumab, possible implication of the syringes used (silicone free or not), possible relation with previous glaucoma or OHT, are all factors that may come into play for eyes developing IOP increase. Currently, physicians undertaking treatment with anti-VEGF agents should be vigilant for this complication and monitor IOP in every visit (before any treatment), especially in eyes with relevant history. In cases of treatment with bevacizumab, there must be caution when the injection is stored for a long time. Another suggestion is to treat, when it is possible, in a 'treat and extend' regimen, extending in this way the interval between injections and possibly reducing the total number of injections. Prospective studies with long followup will be needed to establish the true prevalence and possible correlations of this complication.
